Eli Lilly and Company $LLY Stock Bought by Global Wealth Management Investment Advisory Inc.

by · The Markets Daily

Global Wealth Management Investment Advisory Inc. raised its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 109.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,496 shares of the company’s stock after acquiring an additional 4,968 shares during the period. Eli Lilly and Company makes up 1.4% of Global Wealth Management Investment Advisory Inc.’s portfolio, making the stock its 19th largest holding. Global Wealth Management Investment Advisory Inc.’s holdings in Eli Lilly and Company were worth $10,987,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. BlackRock Inc. grew its position in shares of Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares in the last quarter. State Street Corp increased its holdings in shares of Eli Lilly and Company by 1.7% in the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock worth $43,438,262,000 after purchasing an additional 605,752 shares during the last quarter. Bank of America Corp DE purchased a new stake in shares of Eli Lilly and Company in the second quarter worth about $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after buying an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC boosted its stake in Eli Lilly and Company by 7.9% during the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock valued at $6,550,587,000 after buying an additional 400,538 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the transaction, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on LLY shares. UBS Group raised their price target on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a “buy” rating in a report on Friday, October 30th. JPMorgan Chase & Co. upped their price objective on Eli Lilly and Company from $1,500.00 to $1,650.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. Royal Bank Of Canada increased their target price on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an “outperform” rating in a research report on Friday, October 30th. Finally, HSBC raised their target price on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,416.64.

Get Our Latest Report on Eli Lilly and Company

Eli Lilly and Company Trading Up 4.4%

LLY opened at $1,413.22 on Tuesday. The firm has a market cap of $1.33 trillion, a P/E ratio of 45.87, a P/E/G ratio of 1.77 and a beta of 0.40. Eli Lilly and Company has a 12 month low of $850.51 and a 12 month high of $1,453.00. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The stock has a 50-day moving average of $1,220.13 and a 200 day moving average of $1,102.83.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The company had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. During the same period in the previous year, the firm posted $7.02 earnings per share. The firm’s revenue for the quarter was up 38.6% on a year-over-year basis. As a group, research analysts forecast that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be issued a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s payout ratio is 22.46%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

  • Positive Sentiment: In a Phase 3 trial, Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity in adults with obesity or overweight. Lilly reported up to an average 44% reduction in breathing interruptions and said it plans to seek U.S. FDA approval for the indication by year-end 2026. An additional use could expand the pill’s commercial opportunity and help it compete with Novo Nordisk’s obesity treatments. Article: Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial
  • Positive Sentiment: Jefferies raised its LLY price target to $1,700 from $1,610 and reiterated a Buy rating, signaling continued analyst confidence in the company’s growth outlook. Article: Jefferies raises Eli Lilly price target
  • Positive Sentiment: Lilly is expanding digital access to Zepbound and Foundayo through telehealth partnerships with Hims & Hers and LifeMD, potentially broadening the reach of its branded obesity medicines. Article: Eli Lilly opens digital access to obesity drugs
  • Negative Sentiment: The FDA issued new warnings about a potential serious eye risk associated with GLP-1 drugs, including Zepbound. The safety alert may raise concerns for patients and prescribers, although the reports provided no Lilly-specific change to the drug’s safety profile. Article: FDA orders new eye-risk warnings for Ozempic and Zepbound

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.

Recommended Stories